Warnings of 'no deal' Brexit disintegration for medicines market

With the two Conservatives vying to become Britain's Prime Minister dancing around undeliverable promises, brazenly marching towards cul-de-sacs and engaging in rabble rousing when quizzed on Brexit, the UK pharma and life sciences industry could be excused for some weariness and wariness about the coming months.

Companies had already been preparing for March’s supposed deadline for two years and saw their stockpiling, duplication testing and planning for alternative routes rendered unnecessary as the Brexit date was extended to October 31 and parliament voted down the prospect of a ‘no deal’.

"It is extremely challenging for pharmaceutical companies to be continually preparing for a ‘no-deal’"But members of parliament also repeatedly rejected Prime Minister Theresa May’s deal, creating a crisis that led to her stepping down and the new chance of a no-deal outcome from October 31, when Boris Johnson or Jeremy Hunt will be in charge – barring further surprises.